What Is Precision Medicine? How Genomics and Multi-Omics Drive Targeted Care
Precision medicine is the practice of matching prevention, diagnosis, and treatment to the biological characteristics of an individual patient rather than to the average patient in a disease category. It becomes possible when three things connect: molecular data about the patient (genomics, proteomics, and other omics layers), a measurable marker that links that biology to a clinical outcome (a biomarker), and evidence strong enough to justify acting on it. The McDonnell Genome Institute (MGI) at WashU describes itself as working across genomics, proteomics, and precision medicine, and its technology hubs illustrate the kinds of data generation this approach depends on.
How precision medicine differs from conventional treatment
Conventional, or "one-size-fits-all," medicine typically starts from a diagnosis defined by symptoms, tissue appearance, and population-level statistics. Treatment follows the protocol that works best on average for that diagnosis.
Precision medicine starts from the same diagnosis but adds a molecular question: what is different about this patient's disease that changes which therapy is likely to work?
| Dimension | Conventional approach | Precision medicine approach |
|---|---|---|
| Starting point | Diagnosis by symptoms, histology, population data | Diagnosis plus molecular profile of the patient or tumor |
| Treatment choice | Best average response for the disease group | Therapy matched to a marker or mechanism |
| Failure mode | Some patients do not respond; reason often unknown | Marker-negative patients are identified earlier, but marker-positive patients may still not respond |
| Evidence base | Large randomized trials in broad populations | Trials plus marker-defined subgroups, which are often smaller |
The practical consequence: precision medicine does not replace conventional medicine. It narrows who is likely to benefit from a given intervention and, increasingly, who should avoid it.
The data layers that make matching possible
Genomics
Genomics reads DNA to find inherited variants, somatic mutations, copy-number changes, and structural rearrangements. In precision medicine, this is often the first layer because it is stable, sequenceable from many sample types, and directly actionable when a variant maps to an approved or investigational therapy.
Proteomics and other omics
DNA alone does not tell you what a cell is actually doing. Proteomics measures proteins and their modifications; metabolomics and lipidomics capture small-molecule state. MGI's Mass Spectrometry Technology Access Center lists proteomics, metabolomics, lipidomics, deep-scale PTM (post-translational modification) analysis, native mass spectrometry, and spatial multi-omics MS technologies. These layers matter when the actionable signal is not in the genome — for example, when a protein is overexpressed without a DNA-level explanation.
Multi-omics integration
Multi-omics means combining these layers rather than reading them in isolation. A variant may be present in DNA but not expressed; a protein may be abundant without a corresponding genomic change. Integration is what turns separate measurements into a candidate mechanism.
From sample to actionable insight: the workflow
The general path looks like this. Exact steps vary by institution and assay.
- Sample collection and accessioning. Input: patient tissue, blood, or derived cells. Action: assess quality and quantity, especially for scarce or degraded material. Expected result: a sample that passes the assay's input requirements.
- Data generation. Input: qualified sample. Action: sequencing, mass spectrometry, spatial profiling, or imaging depending on the question. Expected result: raw reads, spectra, or images.
- Processing and QC. Input: raw data. Action: alignment, quantification, normalization, batch assessment. Expected result: a clean feature matrix with documented quality metrics.
- Variant or feature interpretation. Input: processed features. Action: annotate variants, compare to reference databases, rank candidate markers. Expected result: a shortlist of candidates with supporting evidence.
- Functional validation. Input: candidate list. Action: test in model systems. MGI's Genome Engineering & Stem Cell Center lists genome-edited stem cell and cancer cell lines, genome-edited model organisms, patient-derived iPSCs, stem cell differentiation, and CRISPR screening; its Functional Imaging group lists massively parallel genetic cellular screening, drug screening, isolating live cells from specific phenotypes, spatial transcriptomics, and image analysis. Expected result: evidence that the candidate changes a measurable phenotype.
- Clinical decision support. Input: validated marker. Action: match to therapy, trial, or monitoring plan. Expected result: a recommendation that a care team can act on.
Steps 1–5 are where most of the time and cost sit. Step 6 is where the evidence bar is highest.
Where precision medicine is applied
- Biomarker discovery. Finding a measurable feature that predicts response, resistance, or prognosis. This is the bridge between a molecular finding and a clinical decision.
- Variant interpretation. Deciding whether a specific variant is meaningful, uncertain, or benign — the step that determines whether a genomic result changes care.
- Drug screening and functional testing. Testing candidate therapies against patient-derived cells to see what actually kills or inhibits the disease.
- Clinical trial design. Using marker-defined subgroups to enrich trials for likely responders, which is also why such trials are often smaller than traditional ones.
MGI states it has 65 current academic institute partners and 56 current biopharma partners, and reports a 95% repeat partner rate — a signal that multi-omic service work is often repeated rather than one-off.
Limitations and open problems
- Data standards. Different assays, pipelines, and reference versions produce results that are hard to compare across sites. MGI's own news commentary notes that research-grade data standards are critical in clinical trials, particularly with scarce or degraded patient material, where analytical precision determines whether samples can be used at all.
- Evidence requirements. A marker is not a treatment. Moving from association to clinical action requires trials that show acting on the marker improves outcomes.
- Sample constraints. Small biopsies, degraded RNA, and low tumor content limit which assays are feasible.
- Interpretation of uncertain findings. Many variants remain variants of uncertain significance, and multi-omic data can add ambiguity as easily as it resolves it.
- Equity and access. Genomic reference data have historically underrepresented some populations, which affects interpretation accuracy for those groups.
How to decide whether a precision medicine approach fits
Ask three questions before committing:
- Is there an actionable marker for this disease? If no validated marker exists, molecular profiling may generate research value but not a changed treatment plan.
- Can the sample support the assay? Check input requirements before assuming a result is possible.
- What will you do with the result? If the answer is "nothing changes," the data may still be worth generating for research — but that should be the stated goal.
For institutions and research groups, the practical entry point is usually a technology access center or core facility that offers the specific assay layer you need, rather than a single end-to-end product. MGI's structure — separate hubs for genome technology, genome engineering and stem cells, mass spectrometry, and functional imaging — reflects that multi-omic work is assembled from distinct capabilities rather than purchased as one service.